Abstract:Background: The capacity of self-renewal and multipotent differentiation makes mesenchymal stem cells (MSC) one of the most widely investigated cell lines in preclinical studies as cell-based therapies. However, the low survival rate and poor homing efficiency of MSCs after transplantation hinder the therapeutic application. Exosomes derived from MSCs have shown promising therapeutic potential in many diseases. However, the heterogeneity of MSCs may lead to differences in the function of secreting exosomes. In this study, the therapeutic effects of hUC-Exos and hFP-Exos on the DSS-induced colitis mouse model were investigated. Methods: The colitis mouse models were randomly divided into four groups: (1) DSS administered for 7 days and euthanasia (DSS7D), (2) DSS administered for 7 days and kept for another 7 days without any treatment (DSS14D), (3) DSS administered for 7 days and followed with hUC-EVs infusion for 7 days (hUC-EVs) and (4) DSS administered for 7 days and followed with hFP-EVs infusion for 7 days (hFP-EVs). We analyzed colon length, histopathology, Treg cells, cytokines and gut microbiota composition in each group. Results: A large amount of IL-6, IL-17 and IFN-γ were produced along with the decrease in the number of CD4 + Foxp3 + and CD8 + Foxp3 + cells in DSS7D group, which indicated that Th17 cells were activated and Treg cells were suppressed. We found that the number of CD4 + Foxp3 + and CD8 + Foxp3 + cells increased in order to suppress inflammation, but the length of colon did not recover and the symotoms were worsened of the colonic tissue in DSS14D group. The subsequent infusion of either hUC-Exos or hFP-Exos mediated the transformation of Treg and Th17 cells in colitis mice to maintain immune balance. The infusion of hUC-Exos and hFP-Exos also both reduced the abundance of pro-inflammatory intestinal bacterial such as Verrucomicrobia and Akkermansia muciniphila to improve colitis. Conclusions: We found that Foxp3 + Treg cells can inhibit the inflammatory response, and the over-activated Treg cells can still further damage the intestinal mucosa. hUC-Exos and hFP-Exos can control inflammation by regulating the balance between Th17 cells and Treg cells. Decreased inflammatory response improved the structure of colon wall in mice and reduced the abundance of pro-inflammatory bacteria in the intestine. The improvement of intestinal wall structure provides conditions for the reproduction of beneficial bacteria, which further contributes to the reduction of colitis.

Olfactory Ecto-Mesenchymal Stem Cell-Derived Exosomes Ameliorate Experimental Colitis Via Modulating Th1/Th17 and Treg Cell Responses.

Exosomes from mesenchymal stromal cells reduce murine colonic inflammation via a macrophage-dependent mechanism.

Olfactory Ecto-Mesenchymal Stem Cells Possess Immunoregulatory Function and Suppress Autoimmune Arthritis

Mesenchymal Stem Cell-Derived Exosome Mitigates Colitis Via the Modulation of the Gut Metagenomics-Metabolomics-farnesoid X Receptor Axis.

Perinatal tissue-derived exosomes ameliorate colitis in mice by regulating the Foxp3 + Treg cells and gut microbiota

Olfactory ecto-mesenchymal stem cell-derived exosomes ameliorate murine Sjögren’s syndrome by modulating the function of myeloid-derived suppressor cells

Olfactory Ecto-Mesenchymal Stem Cell-Derived Exosomes Ameliorate Murine Sjögren’s Syndrome Via Suppressing Tfh Cell Response

IFN-γ Promoted Exosomes from Mesenchymal Stem Cells to Attenuate Colitis Via Mir-125A and Mir-125B

P175 HucMSC-Exo ameliorate experimental colitis via modulating gut microbiota and metabolites

Mesenchymal Stem Cell-derived Exosomes: Novel Therapeutic Approach for Inflammatory Bowel Diseases

The therapeutic potential of stem cell-derived exosomes in the ulcerative colitis and colorectal cancer

Thermally Engineered Msc-Derived Exosomes Ameliorate Colitis in Mice by Restoring the Imbalanced Th17/Treg Cell Ratio

Therapeutic Prospects of Mesenchymal Stem Cell and Their Derived Exosomes in the Regulation of the Gut Microbiota in Inflammatory Bowel Disease

Immunomodulatory effects of mesenchymal stromal cells-derived exosome

IDDF2018-ABS-0196 Exosomes derived from human IPSC-MSCS protected against TNBS-INDUCED colitis

Adipose‐derived mesenchymal stem cell‐secreted exosome alleviates dextran sulfate sodium‐induced acute colitis by Treg cell induction and inflammatory cytokine reduction

MSCs-exosomes can promote macrophage M2 polarization via exosomal miR-21-5p through Mesenteric injection: a promising way to attenuate murine colitis

Exosomes derived from cancer cells relieve inflammatory bowel disease in mice

MSCs-exosomes Can Promote Macrophage M2 Polarisation Via Exosomal Mir-21-5p Through Mesenteric Injection: A Promising Way to Attenuate Murine Colitis

Exosomes derived from 3D-cultured MSCs improve therapeutic effects in periodontitis and experimental colitis and restore the Th17 cell/Treg balance in inflamed periodontium

Systematic Exposition of Mesenchymal Stem Cell for Inflammatory Bowel Disease and Its Associated Colorectal Cancer